Skip to main content

Table 1 Patient demographic and baseline clinical characteristics

From: Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

Characteristic VEM1-IPI (n = 46)
Age, years  
 Mean (SD) 55.0 (14.20)
Gender, n (%)  
 Male 37 (80.4)
ECOG performance status, n (%)  
 0 35 (76.1)
 1 11 (23.9)
Disease stage at study entry, n (%)  
 III 8 (17.4)
 IV 38 (82.6)
M-stage at study entry, n (%)  
 M0 6 (13.0)
 M1a 8 (17.4)
 M1b 8 (17.4)
 M1c 24 (52.2)
Number of disease sites, n (%)  
 1 2 (4.3)
 2 8 (17.4)
 3 7 (15.2)
 4 4 (8.7)
  ≥ 5 25 (54.3)
  1. ECOG Eastern Cooperative Oncology Group, IPI ipilimumab, SD standard deviation, VEM vemurafenib